January. 26, 2022
Japan Tissue Engineering Co., Ltd.

10th Technology and Management/Innovation Award “METI Minister's Award” Winner“Popularization of Japan’s First Regenerative Medical Product – AutologousCultured Epidermis JACE®”
Japan Tissue Engineering Co., Ltd. (headquartered in Gamagori, Aichi. CEO: Kenichiro Hata) has
announced today of being awarded “METI Minister's Award” in the 10th Technology andManagement/Innovation Award held by Japan Techno-Economics Society (with the support of MIC,MEXT, METI, Nikkei Inc., Nikkan Kogyo Shimbun, Ltd.) for “the popularization of Japan’s firstregenerative medical product, Autologous Cultured Epidermis JACE.”

The Technology and Management/Innovation Award provides recognition to great innovative
examples that have greatly revolutionized the world. The purpose of the award is to introduce
technological and social changes or innovations that are about to cause said changes and theirpractical processes to provide a reference point for the next generation of management and engineers
to promote further innovation.
The award was prompted through the recognition of “the popularization of Japan’s first regenerative
medical product, Autologous Cultured Epidermis JACE” which has become the gold standard fordifficult-to-treat severe burns, contributing to the saving of lives for many patients, its establishment ofcreating a stable supply structure in cooperation with medical facilities, as well as through over 1,000
successful transplants.
[The award details are as follows]
Awarded Organization Japan Tissue Engineering Co., Ltd.
Enterprise Name

Popularization of Japan’s First Regenerative Medical Product, AutologousCultured Epidermis JACE

Summary

The Autologous Cultured Epidermis JACE,(heretofore known as JACE) cultures thepatient’s own skin cells to fabricate anepidermal cell sheet for transplant use. Thisis Japan’s first regenerative medical
product and has been approved in 2007 forproduction and sale for use with extensive
severe burn treatment as well as beingprescribed for by insurance in 2009 (Fig. 1).
Afterwards, medical facilities and patientadvocacy groups have expressed a strong
demand for it, leading to expanding of Fig. 1 Autologous Cultured Epidermis JACE
approval for use on congenital melanocytic
nevus in 2016 and epidermolysis bullosa in 2018. JACE has greatly
contributed to saving the lives of and improving the quality of life forpatients with refractory conditions. This has been used for the treatment ofa variety of severe burn patients from incidents such as the 2013
Fukuchiyama fireworks accident, 2015 New Taipei water park fire, 2019Japan Tissue Engineering Co., Ltd., 6-209-1 Miyakitadori, Gamagori, Aichi 443-0022, Japan. URL: https://www.jpte.co.jp

1/2

Kyoto arson attack. It has become popularized for as a standard treatment
procedure domestically as well as becoming highly regarded whenprovided as international support.
JACE has been in development since the times when our nation’s
pharmaceutical administration did not have a category for regenerative
medicine. It has received pharmaceutical approval as a medical device,
but the 2014 amendment to the Pharmaceutical Affairs Law created a new
category for regenerative medical products, and thus, it was renamed as
Japan’s first regenerative medical product. The development of JACE has
not only opened the door to the heavily regulated Pharmaceutical Affairs
Law, but also promoted the possibilities of regenerative medicine industryof our nation, building the foundation of regenerative medicine
development where Japan leads in the world.
Our company will continue to aim towards the goal of “Creating a Future for Regenerative Medicine”
and to improve the patient quality of life.
List of award winners for the “10th Technology and Management/Innovation Award”:(The information is in Japanese)

https://www.jates.or.jp/management_study/management_of_technology_meeting/gikei_innovation_201607/10th_Kettei.html(Reference: About J-TEC)
J-TEC is a maker of regenerative medical products whose corporate vision is “creating a futurefor regenerative medicine”. J-TEC is a member of the Teijin Group. As Japan’s top runner inregenerative medicine, J-TEC obtained marketing approval for autologous cultured epidermis“JACE”, Japan’s first regenerative medical product, in October of 2007, and began marketing theproduct in January of 2009. J-TEC then went on to obtain marketing approval for Autologous
Cultured Cartilage “JACC” in July of 2021, for Autologous Cultured Corneal Epithelium “Nepic” inMarch of 2020, and for Autologous Cultured Oral Mucosal Epithelium “Ocural” in June 2021. “JACC”
was Japan’s first regenerative medical product for use in orthopedic surgery, and “Nepic” was thefirst for use in ophthalmology. Of the 16 regenerative medical products that have been approved inJapan, four are J-TEC products.
[Contact information for inquiries about this announcement]
Japan Tissue Engineering Co., Ltd.
Business Planning Department
TEL0533-66-2020
E-mail jtec-info@jpte.co.jp

Japan Tissue Engineering Co., Ltd., 6-209-1 Miyakitadori, Gamagori, Aichi 443-0022, Japan. URL: https://www.jpte.co.jp

2/2